Equities Analysts Issue Forecasts for TENX FY2024 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities researchers at Roth Capital cut their FY2024 earnings estimates for Tenax Therapeutics in a report issued on Wednesday, March 5th. Roth Capital analyst J. Aschoff now forecasts that the specialty pharmaceutical company will earn ($1.20) per share for the year, down from their previous estimate of ($1.16). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.80) EPS and FY2029 earnings at $3.73 EPS.

Several other brokerages have also recently weighed in on TENX. Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a research note on Monday. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Price Performance

Shares of Tenax Therapeutics stock opened at $6.19 on Monday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $7.89. The company’s fifty day moving average is $6.44 and its 200 day moving average is $5.21.

Institutional Trading of Tenax Therapeutics

Institutional investors have recently bought and sold shares of the company. Vestal Point Capital LP bought a new position in shares of Tenax Therapeutics during the 3rd quarter worth about $288,000. Sphera Funds Management LTD. bought a new position in shares of Tenax Therapeutics during the 3rd quarter worth about $101,000. Stonepine Capital Management LLC bought a new position in shares of Tenax Therapeutics during the 3rd quarter worth about $173,000. Two Sigma Investments LP bought a new position in shares of Tenax Therapeutics during the 4th quarter worth about $84,000. Finally, Millennium Management LLC bought a new position in shares of Tenax Therapeutics during the 4th quarter worth about $166,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.